How Stanozolol Affects HDL Cholesterol

Stanozolol suppresses HDL cholesterol via a potent first-pass hepatic mechanism driven by its 17-alpha-alkylated oral structure:

1. Hepatic lipase (HTGL) upregulation: As a 17-alpha-alkylated oral, stanozolol survives first-pass liver metabolism intact, delivering a sustained, concentrated androgenic signal to hepatocytes. This directly and powerfully upregulates hepatic triglyceride lipase (HTGL), the primary enzyme responsible for catabolising HDL particles. HTGL elevation precedes and drives the fall in HDL.
2. Rapid HTGL surge: Applebaum-Bowden (1987) documented HTGL activity surging 230% within just 3 days of stanozolol initiation, before HDL itself has substantially fallen. This HTGL surge is the mechanistic trigger for HDL decline.
3. ApoA-I suppression: Stanozolol reduces apolipoprotein A-I (ApoA-I) by approximately 40%. ApoA-I is the structural and functional protein of HDL particles; fewer ApoA-I molecules means fewer HDL particles can be synthesised and maintained.
4. No aromatisation buffer: Stanozolol does not aromatise to estradiol. Estradiol has well-characterised HDL-preserving effects (suppressing HTGL gene expression). The absence of estrogenic protection removes any counterbalance to direct hepatic lipase stimulation.
5. HDL2 subfraction targeted: The HDL2 subfraction, which performs most of the cardioprotective reverse cholesterol transport, is disproportionately reduced (Thompson 1989 showed HDL2 fell 71% versus 33% for total HDL). HDL3, the less protective subfraction, is less affected.

At 6 mg/day (the lowest dose studied in controlled trials, Thompson 1989):

• Total HDL: -33% (from ~59 to ~40 mg/dL in that cohort)
• HDL2 subfraction: -71% (virtually eliminated)
• LDL: +29%
• HTGL activity: +123%

At bodybuilding doses (25-50 mg/day):

• Total HDL suppression of 50-70% is expected based on dose-response extrapolation
• HDL commonly falls below 20 mg/dL, sometimes below 15 mg/dL
• Haffner (1983) documented HDL falling from 59 to 29 mg/dL in a separate cohort at comparable doses
• The combination of HDL suppression and LDL elevation creates a severely atherogenic lipid profile

Timing: HTGL surges within 24-72 hours. HDL begins falling measurably by days 3-7. Maximum suppression is reached by weeks 3-4.

Stacking amplification: Adding stanozolol to a testosterone or trenbolone base dramatically compounds the lipid damage beyond either compound alone. Each compound independently suppresses HDL through different mechanisms.

Baseline lipid panel is mandatory before starting stanozolol:

• Do not start if pre-cycle HDL is already below 35 mg/dL; the additional suppression will push you into the danger zone (below 20 mg/dL)
• Establish baseline LDL, total cholesterol, and ideally ApoB

On cycle:

• Check lipids at week 3-4. This is not optional; HTGL-driven damage occurs early and rapidly
• If HDL has fallen below 20 mg/dL, this is a strong indication to stop the compound
• If HDL has fallen below 15 mg/dL, discontinuation is strongly recommended

Post-cycle:

• Recheck at 4 weeks post-cessation, then again at 8 weeks to confirm recovery
• Recovery of HDL after stanozolol typically occurs within 4-12 weeks of stopping the compound

During cycle (harm reduction):

• Keep cycles short: 4-6 weeks maximum. Duration determines cumulative arterial exposure to a severely atherogenic lipid environment.
• Do not stack with other hepatotoxic orals: Adding dianabol, anadrol, or other 17-AA compounds to stanozolol compounds both the lipid damage and hepatotoxicity synergistically.
• Cardiovascular exercise: 30-45 minutes, 4-5 times per week of moderate-intensity cardio is the single most effective mitigation strategy. Cardio directly raises HDL production independent of HTGL activity.
• Omega-3 fatty acids: 3-4 g EPA/DHA daily. Reduces triglycerides, has mild anti-HTGL effects, and supports endothelial health.
• Citrus bergamot: 500-1000 mg/day. Modest evidence for HDL support and LDL reduction.
• Consider dropping if HDL falls below 20 mg/dL: Below this threshold, reverse cholesterol transport is critically impaired and the atherogenic risk is severe.

Compound selection context:

• Stanozolol is the oral steroid of choice when a "dry," non-aromatising compound is desired, but its lipid profile is the worst of any commonly used AAS in controlled trials. Users who are concerned about cardiovascular health should consider whether any aesthetics benefit justifies this lipid cost.